Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E. Rosenberg, Robert Dreicer, Jean Hoffman‐Censits et al.|The Lancet|2016Cited by 3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Petros Grivas et al.|The Lancet|2016Cited by 2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Toni K. Choueiri et al.|The Lancet|2020Cited by 1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaThomas Powles, Petros Grivas, Se Hoon Park et al.|New England Journal of Medicine|2020Cited by 1.5k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun Vasant Balar, Joaquim Bellmunt, Daniel Castellano et al.|The Lancet Oncology|2017Cited by 1.3k